U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06980025) titled 'Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial' on May 12.
Brief Summary: This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth at less than 35 weeks gestation who are randomized to either 162 mg aspirin or 81 mg aspirin daily. The study drug will be initiated between 10 and 15 weeks gestation and continued through 36 weeks, 6 days gestation. The primary endpoint is recurrent preterm delivery or fetal death prior to 35 weeks, 0 days gestation.
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Preterm Delivery...